wherein:

X_1, X_2 and X_3 are either all carbon atoms or one of X_1, X_2 and X_3 is a nitrogen atom;

n is 0 or 1;

R_1 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or a group of the formula:

—Y—X—Z

wherein

Y is absent or a (1-2C)alkylene;

X is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R^{A3})—, —N(R^{A3})—C(O)—, —N(R^{A3})—C(O)O—, —C(O)—N(R^{A3})—, —N(R^{A3})C(O)N(R^{A3})—, —SO_2—, —$S(O)_2$N(R^{A3})—, or —N(R^{A3})SO_2— wherein R^{A3} is selected from hydrogen or (1-2C)alkyl; and

Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;

and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, $NR^{A6}R^{A7}$, —$(CR^{A4}R^{A5})_p$—$NR^{A6}R^{A7}$ (wherein p is selected from 1, 2 or 3), (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, aryl, aryloxy, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl or heteroaryl-(1-2C)alkyl; wherein R^{A4} and R^{A5} are each independently selected from hydrogen or (1-4C)alkyl; and wherein R^{A6} and R^{A7} are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkyl amino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or R^{A6} and R^{A7} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring; and

R_2 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or R_2 is selected from:

(i) —$C(O)OR_{2A}$, wherein R_{2A} is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl; or

(ii) —$C(O)NR_{2B}R_{2C}$; wherein R_{2B} and R_{2C} are each independently selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl.

6. A combination product according to claim **1**, wherein the β-lactamase inhibitor is a compound of Formula Ic, shown below:

Formula Ic



wherein:

n is 0 or 1;

R_1 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or a group of the formula:

—X—Z

wherein

X is —OC(O)—, —N(R^{A3})—C(O)— or —C(O)—N(R^{A3})—, wherein R^{A3} is selected from hydrogen or (1-2C)alkyl; and

Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;

and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, $NR^{A6}R^{A7}$, —$(CR^{A4}R^{A5})_p$—$NR^{A6}R^{A7}$ (wherein p is selected from 1, 2 or 3), (1-4C)alkoxy, (1-4C)alkyl or (1-4C)alkanoyl; wherein R^{A4} and R^{A5} are each independently selected from hydrogen or (1-4C)alkyl; and R^{A6} and R^{A7} are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkylamino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or R^{A6} and R^{A7} can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

R_2 is a substituent of the formula —$C(O)OR_{2A}$, wherein R_{2A} is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl or (1-4C)alkanoyl.

7. A combination therapeutic product according to claim **1**, wherein the β-lactamase inhibitor is selected from one of the following compounds, or a pharmaceutically acceptable salt thereof: